They say good things come in threes. If so, biotech companies could be in for not just another year of outperformance, but another decade. The first era of biotech was a building phase, when companies created their first blockbuster drugs. The second, current one, has resulted in a four-year rally that reflects the sector’s transition from a cluster of one-hit […]
More Charts
So are stock prices too high or aren’t they?One of the most closely watched measures of stock market value is the cyclically adjusted price-earnings (CAPE) ratio. Popularized by Nobel-prize winning economist Robert Shiller, CAPE is calculated by taking the S&P 500 and dividing it by the average of ten years’ worth of earnings. If the ratio is above the […]
In fact, biotech stocks have been so strong that “you could see these stocks off another 10 percent from here, and still be in an uptrend,” Johnson said. “We’d be buying these names on the pullback.”The fundamentals also remain supportive of biotech, says David Seaburg, head of equity sales trading with Cowen & Co.”From a valuation perspective, this is not […]
In fact, biotech stocks have been so strong that “you could see these stocks off another 10 percent from here, and still be in an uptrend,” Johnson said. “We’d be buying these names on the pullback.”The fundamentals also remain supportive of biotech, says David Seaburg, head of equity sales trading with Cowen & Co.”From a valuation perspective, this is not […]
Biotech bubble may just be an optical illusion
By iCELL News on March 27, 2015 · Sector
SAN FRANCISCO (MarketWatch)—The stellar performance of biotechnology stocks in the past few years has predictably sparked fears of an impending crash. But for all the talk of a bubble, biotechs are far from being overbought, according to analysts at Credit Suisse.“There are optics suggesting that […]
Wikimedia CommonsThere is probably a bubble in biotech stocks. In a big note on published on Friday, analysts at Credit Suisse ask if we’re in a biotech bubble, and answer that no, it’s not a bubble, merely a “new era” for biotech stocks. Which is exactly what it sounds like when something is a bubble. Credit Suisse hinges its argument on what it […]
View gallery.(Wikimedia Commons)There is probably a bubble in biotech stocks.
In a big note on published on Friday, analysts at Credit Suisse ask if we’re in a biotech bubble, and answer that no, it’s not a bubble, merely a “new era” for biotech stocks. Which is exactly what it sounds like when something is a bubble. Credit Suisse hinges its argument on what […]
Credit Suisse on Biotech’s Nirvana Phase
Posted March 27, 2015 by Joshua M Brown
There’s a really interesting piece of research out from Credit Suisse in which Ravi Mehrotra & Co lay out an “It’s different this time” thesis that seeks to explain why the huge rally in biotech stocks is justified and possibly not over yet.
They note that there are indeed […]
Akin Oyedele
Feb. 19, 2015, 4:24 AM
12,898
The global stock market looks very different today than it did 115 years ago.From Credit Suisse’s new Global Investment Returns Yearbook:”Figure 1 shows the relative market capitalizations of world equity markets at our base date of end-1899. Figure 2 shows how they had changed by end-2014. Markets that are not included in the Yearbook dataset […]
They say good things come in threes. If so, biotech companies could be in for not just another year of outperformance, but another decade. The first era of biotech was a building phase, when companies created their first blockbuster drugs. The second, current one, has resulted in a four-year rally that reflects the sector’s transition from a cluster of one-hit […]
